To understand the relationship between oncogenic signaling and the reprogramming of gene expression, we performed transcriptional profiling in rat ovarian surface epithelial cells (ROSE), in which neoplastic transformation is driven by a mutated KRAS oncogene. We identified 4200 genes whose expression was elevated or reduced following permanent KRAS expression. Deregulated KRAS-responsive genes encode transcriptional regulators, signaling effectors, proteases, extracellular matrix and adhesion proteins, transformation-suppressing proteins and negative growth regulators. Many of them have not been previously identified in cells expressing oncogenic RAS genes or in other well-studied models of oncogenic signaling. The number of critical genes related to the execution of anchorage-independent proliferation and epithelialmesenchymal transition was narrowed down to 79 by selectively inhibiting the mitogen-activated protein kinase (MAPK/ERK) and phosphatidylinositol 3-kinase (PI3K) pathways. Blocking MAPK/ERK-signaling caused reversion to the normal epithelial phenotype in conjunction with the reversal of deregulated target transcription to pretransformation levels. In addition, silencing of the overexpressed transcriptional regulator Fra-1 by RNA interference resulted in growth reduction, suggesting that this factor partially contributes to, but is not sufficient for the proliferative capacity of KRAS-transformed epithelial cells.
Introduction
Ras gene mutations are prevalent in human and experimental cancer. Mutated Ras proteins play a critical role in determining malignancy both in cell culture and animal models of cancer (Bishop, 1985; Bos, 1989; Johnson et al., 2001) . Ras mutations are thought to mediate malignant phenotypes by three major mechanisms: activating Ras mutations result in short-term effects on cellular signaling (Barbacid, 1987; Downward, 2001) . Oncogenic Ras signal transduction exerts longterm alterations on the transcriptional program (Campbell et al., 1998; Malumbres and Pellicer, 1998) . In addition, Ras mutations may give rise to rapid secondary alterations in the affected cells by inducing chromosomal aberrations and genetic instability (Denko et al., 1994) .
In normal cells, Ras proteins function as guanosine diphosphate/guanosine triphosphate (GDP/GTP)-regulated switches and serve as points of convergence for diverse extracellular signal-stimulated pathways regulating proliferation and differentiation. Ras activation involves the transition from the inactive GDP-bound to the GTP-bound state. This step is promoted by a guanine nucleotide exchange factor after activation of receptor tyrosine kinases. The exchange factor is recruited by an adapter molecule to the receptor at the plasma membrane, where it can contact and activate Ras. Signal transduction downstream of Ras is mediated through various effector enzymes and pathways. The serine/threonine kinase Raf activates the mitogenactivated protein kinase (MAPK/ERK) pathway, the lipid kinase phosphatidylinositol 3-kinase (PI3K) activates the serine/threonine kinase PKB/AKT and the GTPase Rac, and the nucleotide exchange factor Ral-GDS activates the Ras-related protein Ral. In addition, several other proteins share properties of Ras effectors due to their preferential binding to Ras-GTP (Campbell et al., 1998; Malumbres and Pellicer, 1998) .
Oncogenic forms of RAS are locked in their active, GTP-bound state and confer essential features of malignancy on non-neoplastic cells such as cell cycle progression, protection against apoptotic stimuli, motility, invasiveness and angiogenesis (Malumbres and Pellicer, 1998) . Several lines of evidence suggest that the Raf/MEK/ERK pathway functions to control cell cycle progression and transformed phenotypes (Marshall, 1996) . Activation of the PI3K/PKB/AKT pathway is thought to be responsible for cell survival. However, the phenotypic consequences of the two pathways are not fully distinct, since the Raf/MEK/ ERK pathway can protect against programmed cell death and the PI3K/PKB/AKT pathway can affect cell cycle progression (Downward, 1998b) . Recent studies have indicated a significant contribution of the Ral pathway (Hamad et al., 2002) and of Notch-1 signaling (Weijzen et al., 2002) to neoplastic transformation in human cells. The link between cytoplasmic signaling and the transcriptional machinery is achieved by kinases that pass the nuclear membrane and activate transcriptional regulators. The Raf/MEK/ERK pathway stimulates the ETS-domain transcription factor Elk1, serum-responsive factor (SRF), activation transcription factor 2 (ATF2) and the leucine zipper protein Jun, while PKB/AKT signals modulate the activity of forkhead transcription factors and NF-kB (Campbell et al., 1998; Downward, 1998a; Malumbres and Pellicer, 1998) .
Despite the decisive role in tumorigenesis, only few studies have assessed gene expression patterns modified by oncogenic Ras signaling in a global way. Previously, we have reported gene expression profiles of normal immortalized fibroblasts and transformed derivatives expressing mutant HRAS, KRAS and NRAS genes (Zuber et al., 2000) . Others have described the transcriptional effects by Ras in mast cells (Brem et al., 2001) and by the Ras effector Raf in a mammary epithelial cell line (Schulze et al., 2001) . Since the precursor cells predominantly affected by genetic damage to any of the Ras genes are epithelial cells giving rise to carcinomas, it is desirable to analyse Rasinduced long-term transcriptional alterations in transformed epithelial cells relative to phenotypically normal counterparts. We chose to analyse the transcriptional program mediated by expression of mutated KRAS in a rat cell culture model of ovarian surface epithelium (ROSE). The biology of immortalized rodent cells, unlike human cells (Hahn et al., 1999) , permits neoplastic transformation in one step.
To identify differentially expressed genes associated with KRAS-induced transformation, we chose subtractive suppression hybridization (SSH), a powerful technique independent of preselected gene sets on microarrays (Diatchenko et al., 1996; Zuber et al., 2000) . We recovered genes encoding positive and negative regulators of cellular transformation, of survival, angiogenesis and invasiveness. By treatment of KRAS-transformed ROSE cells with specific signaling inhibitors, we identified subsets of target genes responding to the MEK and PI3K pathways downstream of Ras. Notably, continuous mutant KRAS expression is coupled with the downregulation of more than 20 genes exhibiting growth-inhibitory or transformation suppressor functions.
Results

Properties of normal and transformed ROSE cells used for surveying KRAS-induced transcriptional alterations
ROSE 199 is a spontaneously immortalized cell line derived from the continuous passage of primary rat ovarian surface epithelial cells. ROSE 199 cells express epithelial and mesenchymal characteristics, do not transform spontaneously in vitro and exhibit normal p21 Waf1 and very low p53 protein levels (data not shown). In dense cultures, the cells form multilayers resembling histologically serous papillary cystadenomas of borderline malignancy. We generated a stable KRAStransformed derivative of ROSE 199 cells, designated ROSE A2/5. The cells exhibit epithelial-mesenchymal transition (EMT) (Figure 1a ), anchorage-independent proliferation ( Figure 1b ) and elevated levels of phosphorylated p42/44 ERK ( Figure 1c ). Ras-transformed ROSE cells represent a late stage in ovarian transformation (Auersperg et al., 1999) . Stable KRAS-transfectants are instrumental in establishing a catalog of transcribed sequences indicative of both primary and secondary alterations related to the transformed phenotype. Although conditional expression of Ras oncogenes may permit detection of the immediate effects of signaling, the transcriptional response may be obscured by rapidly and transiently induced chromosomal abnormalities as well as genomic instability (Denko et al., 1994; Saavedra et al., 2000) . Moreover, we have shown previously that key features of mRNA expression profiles in conditionally HRAS-transformed fibroblasts overlap significantly with those in stable transfectants, which maintain a near (Zuber et al., 2000) . To avoid transcriptional alterations reflecting differences of density-inhibited versus proliferative cells and immediate effects of growth factor stimulation (Fambrough et al., 1999; Iyer et al., 1999; Zavadil et al., 2001) , we compared the expression profiles of ROSE 199 and A2/5 cells strictly maintained in exponential growth phase.
Profiling transcriptional alterations related to permanent activation of the KRAS oncogene
We recovered fragments of genes differentially expressed in normal ROSE 199 and KRAS-transformed A2/5 cells from two subtracted cDNA libraries established after subtractive suppression hybridization (SSH) (Diatchenko et al., 1996) . In the forward subtraction, we mixed tester cDNA prepared from ROSE 199 mRNA, digested with the restriction enzyme RsaI and ligated to adapter sequences with excess driver cDNA synthesized from A2/5 mRNA. Sequences recovered by PCR using adapter primers represent genes expressed in normal ROSE cells and downregulated in the KRAS-expressing derivative. To obtain sequences upregulated or de novo expressed in A2/5 cells, we permutated tester and driver cDNAs (reverse subtraction). Overall, we determined the nucleotide sequence of 1070 subtracted cDNA clones obtained after T/A-cloning and bacterial transformation and identified 568 individual sequences. We verified differential expression by two independent methods: Firstly, we reamplified the subtracted cDNA sequences by PCR using nested adapter primers, gelfractionated the PCR products and transferred them to nylon membranes. We hybridized duplicate membranes with 32 P-labelled cDNA probes derived from normal ROSE 199 or transformed A2/5 cells, respectively (reverse Northern analysis) (von Stein et al., 1997) (Figure 2 ). Secondly, we performed conventional Northern analysis of total RNA prepared from the two cell lines using individual cDNA fragments as probes (Figure 3) . Table 1 lists the differentially expressed genes (n ¼ 192), classified with respect to selected functional properties of their products, expressed sequence tags without known function (n ¼ 140) and sequences without match in the databases (n ¼ 35). In all, 157 gene fragments recovered in the two subtracted cDNA libraries did not show any significant differential expression. Totally, 44 sequences were below the detection limit of reverse Northern analysis. However, we assume that approx. 60% of the low-abundance transcripts are differentially expressed as well, as indicated by the proportion of verified genes and ESTs.
Inhibition of Raf/MEK/ERK signaling reverts transcriptional alterations of a subgroup of Ras-responsive genes and causes partial loss of transformed properties
The transcriptional profiles of normal ROSE 199 and KRAS-transformed A2/5 cells differ by 4200 genes (Table 1) . Several questions emerge from the catalog of differentially expressed genes: Do individual signaling pathways downstream of KRAS impinge on limited sets of target genes? How many target genes are essential for executing the neoplastic phenotype? Which targets are secondary to the process of cellular transformation or are irrelevant for growth control? To address these questions, we treated A2/5 cells with inhibitors of effector kinases downstream of Ras and monitored the effects on transcription patterns and phenotype. The MEK inhibitor PD 98059 (Dudley et al., 1995) induced a partial reversion of transformation and epithelialmesenchymal transition as indicated by an epitheliallike morphology similar to ROSE 199 cells ( Figure 1a ) and a reduced capacity of anchorage-independent proliferation (Figure 1b) . The levels of phosphorylated p42 ERK and p44 ERK were reduced in the phenotypically reverted cells (Figure 1c) . Next, we isolated RNA from inhibitor-treated cells and controls and probed 181 differentially expressed genes on Northern blots. The mRNA levels of 98 target genes (54%) were sensitive to inhibitor treatment. Representative examples are shown in Figure 4a and b. The entire set of MEK-sensitive genes is shown in Table 2 . Expression of 19 genes downregulated in KRAS-transformed cells was completely restored to pretransformation levels. Expression of 27 downregulated genes was elevated to an intermediate level. Moreover, mRNA levels related to 39 upregulated genes were completely reduced to those in nontransformed ROSE 199 cells. Expression of 13 upregulated genes was partially diminished. Thus, blocking the Raf/MEK/ERK pathway defines a subset 
Contribution of PI3K-signaling to target gene transcription
To assess the role of phosphatidylinositol 3-kinase (PI3K) in mediating Ras-dependent transcriptional changes, we treated ROSE A2/5 cells with the inhibitor LY 294002 (Vlahos et al., 1994) . Inhibitor concentrations of 410 mM resulted in rapid loss of cell viability (not shown) and intact RNA could not be obtained. We chose an inhibitor concentration of 10 mM, which reduced anchorage-independent proliferation of A2/5 cells approximately 50% (Figure 5a -c), but had no significant effect on morphology and EMT (not shown). Under these conditions, the inhibitor did not affect downregulation of Ras-responsive targets (Table 2 , left part; Figure 4a ). However, the elevated expression of 27 of 84 (32%) genes analysed was diminished or restored to low pretransformation levels in the presence of inhibitor (Table 2, Figure 4b ). Of the 27 upregulated target genes sensitive to PI3K-inhibition, 19 were costimulated via MAPK-signaling, since PD 98059-treatment blocked enhancement of mRNA expression, while eight targets were sensitive to LY 294002 only ( Table 2 ). The levels of the phosphorylated PI3K substrate PKB/AKT were near the detection limit in exponentially growing ROSE 199 cells relative to those in the SKOV3 ovarian carcinoma line harboring an amplified PI3K gene (PIK3CA) (Figure 5a ) (Shayesteh et al., 1999) . Mutant KRAS expression did not elevate the steadystate levels of PKB/AKT, however, activated PKB/AKT protein was undetectable in A2/5 cells treated with 10 mM LY 249002 (Figure 5a,b) . This suggests that PI3K is controlled by a KRAS-independent upstream signal and that upregulation of the PI3K-dependent targets is mediated by downstream effector proteins other than PKB/AKT (Toker, 2000) . Increased levels of phosphorylated p42 ERK and p44 ERK were present in A2/5 cells treated with LY 294002 relative to untreated cells (Figure 5b) . Previously it was shown that the PI3K inhibitor can enhance MEK activity by lifting an inhibitory cross-regulation involving phosphorylation of Raf by PKB/AKT, which unfolds a binding site for the negative Raf-regulating protein 14-3-3 (Zimmermann and Moelling, 1999) . The forced stimulation of the MAPK pathway in A2/5 cells exposed to LY 249002 may thus result in a robust repression of target gene transcription. We cannot formally rule out the possibility that PI3K-mediated target regulation is mediated by the intrinsic protein kinase activity of the lipid kinase (Bondeva et al., 1998; Toker, 2000) . However, inhibition of PI3K reversed transcriptional upregulation of only a subset of upregulated MEK/ERK targets rendering Table 1 for the gene list Transcriptome profiling in KRAS transformation OI Tchernitsa et al ESTAA716162  ESTAA964692  ESTAL110126  ESTAA031051  ESTAA800701  ESTAA965222  ESTAL137303  ESTAA059962  ESTAA800799  ESTAA998174  ESTH31730  ESTAA119143  ESTAA801451  ESTAI007649  ESTNM_016462  ESTAA120390  ESTAA818800  ESTAI011263  ESTW78584  ESTAA170996  ESTAA818930  ESTAI011822  ESTW79960  ESTAA175221  ESTAA819065  ESTAI012613  ESTW89685  ESTAA199109  ESTAA833123  ESTAI020004  ESTAI111475  ESTAA208471  ESTAA833164  ESTAI030422  ESTZ21669  ESTAA216984  ESTAA848932  ESTAI045553  ESTAA245485  ESTAA851396  ESTAI047865  ESTAA245736  ESTAA852038  ESTAI048523  ESTAA408994  ESTAA859541  ESTAI072879  ESTAA438102  ESTAA859885  ESTAI098501  ESTAA459094  ESTAA874786  ESTAI111475  ESTAA472125  ESTAA875301  ESTAI136895  ESTAA472551  ESTAA875353  ESTAI170809  ESTAA499428  ESTAA880764  ESTAI178381  ESTAA530598  ESTAA891207  ESTAI230838  ESTAA545726  ESTAA924598  ESTAI407426  ESTAA596644  ESTAA944528  ESTAI550826  ESTAA616118  ESTAA956476  ESTAI551612  ESTAA620224  ESTAA960059  ESTAK001262  ESTAA673854  ESTAA964182  ESTAK023915  ESTAA710604  ESTAA964504  ESTAK026350  Upregulation  ESTAA033299  ESTAA892448  ESTNM_014394  ESTAA105844  ESTAA893982  ESTNM_017824  ESTAA168172  ESTAA896712  ESTNM_018017  ESTAA168833  ESTAA942775  ESTNM_018323  ESTAA203882  ESTAA955634  ESTW13245  ESTAA231999  ESTAA981941  ESTW48383  ESTAA423523  ESTAI007801  ESTAA438124  ESTAI009898  ESTAA511219  ESTAI010163  ESTAA516783  ESTAI013714  ESTAA536651  ESTAI044498  ESTAA544605  ESTAI044735  ESTAA560946  ESTAI115302  ESTAA562949  ESTAI170552  ESTAA614884  ESTAI180454  ESTAA689719  ESTAI548840  ESTAA79160 ESTAK009324
Transcriptome profiling in KRAS transformation OI Tchernitsa et al transcriptional effects due to activation of MAPK by PI3K unlikely. The targets T043 (proteasome subunit p42), T044 (quinone reductase), T055 (p21-Arc) and T071 (endoplasmic reticulum ATPase) appear to be specifically dependent on PI3K signaling, because the block to upregulation in LY 249002-treated cells was complete and PD 98059 had no effect (Table 2 ). Elevated mRNA of the targets T07 (ras-related protein p23), T022 (21 kDa signal peptidase), T029 (amphiphysin) and T062 (protease-nexin 1) were only partially diminished by LY 249002 and unaffected by PD 98059, suggesting cooperative regulation by the PI3K pathway and alternate signaling pathways.
Contribution of the transcriptional regulator Fra-1 to loss of growth control in KRAS-transformed ROSE cells
The inhibitor studies are helpful in narrowing down the number of target genes responsible for phenotypic properties of KRAS-expressing ovarian epithelial cells. However, they fall short of proving any causal relationships between individual deregulated genes and cellular phenotypes. The conventional way for assessing the functional role of Ras-responsive genes would be the forced expression of given candidates in appropriate recipient cells. Blocking the transformed phenotype in A2/5 cells or inducing certain aspects of transformation in normal ROSE cells could be used as a phenotypic read-out. However, the expression levels observed in the ROSE A2/5 cell system are difficult to mimic in gene transfer experiments. Therefore, we decided to use the recently described technique of RNA interference in mammalian cells (Elbashir et al., 2001) for assessing the functional role of the transcriptional regulator Fra-1 in KRAS-mediated proliferation. We chose the target gene Fra-1, because it is upregulated 4100-fold in HRAS-transformed fibroblasts (Zuber et al., 2000) and in KRAS-transformed ovarian epithelial cells (Table 1) relative to their normal cellular counterparts. Although the transforming activity of Fra-1 is weaker than that of other Fos proteins (Jochum et al., 2001) , Fra-1 can induce morphological transformation, invasiveness and motility in normal cells (Kustikova et al., 1998) . We transiently introduced RNA-duplexes targeted against endogenous Fra-1 into A2/5 cells by lipofection. We confirmed the silencing effect in cellular lysates by analysing Fra-1 proteins 24 and 48 h after introduction of siRNA (Figure 6a ). The downregulation of Fra-1 protein levels reduced proliferation of A2/5 cells by 50% (Figure 6b ). In contrast, silencing KRAS [C12V] expression with a specific siRNA resulted in an almost complete growth inhibition (Figure 6b ). Despite this strong effect, the reduction of the oncoprotein occurred in a short interval only. The p21
Ras levels dropped as early as 4 h after introduction of siRNA, but were as high as in untreated cells after 24 h (not shown). Accordingly, Fra-1 levels were high 24-48 h after treatment with KRAS [C12V] siRNA (Figure 6a ). We did not observe any effect of Fra-1 silencing on EMT (not shown). This suggests that the target gene Fra-1 partially contributes to cell growth and survival, but does not affect the transformed properties of KRAS-expressing ROSE cells.
Discussion
Transcriptional signature of transformed ovarian epithelial cells emphasizes the central role of KRAS-signaling in tumor progression
Although oncogenic RAS proteins exert tremendous effects on gene transcription (Campbell et al., 1998) 
17 novel sequences were found downregulated; 18 novel sequences were found upregulated. Clone names N01-N097 correspond to genes downregulated on Ras transformation, T01-T081, T085-T088 to upregulated genes; differential expression confirmed by northern analysis (see Figure 3 ). Clones N098-N104 refer to downregulated genes, T082T084 to upregulated genes; -differential expression verified by reverse Northern analysis (not shown (Table 3) were independently identified in a cell culture model of normal and HRAStransformed fibroblasts (Zuber et al., 2000) . Stable KRAS-expression in the ROSE model of ovarian carcinoma stimulated transcription of genes capable of controlling cell signaling, gene activity, proteolysis, angiogenesis, invasion and metastasis (Tables 1 and 3). Perhaps the most prominent feature of KRAS-transformed ROSE cells is the complete downregulation of a multitude of transcriptional targets, particularly of genes capable of adversely affecting growth factor-induced signal transduction, transformation and tumor progression (Tables 1 and 3 ). Complete loss of mRNA expression indicates total functional loss. Interestingly, functional impairment in ovarian cancer has been previously shown for 10 of the downregulated Ras-responsive genes (Table 3 ). The remaining negative growth regulators have been implicated in other types of cancer. Their role in the neoplastic transformation and progression of the ovarian epithelium remains to be analysed. Overall, the transcriptional profile of KRAStransformed epithelial cells supports the notion that a cellular oncogene, once activated, can act in a pleotrophic manner to ultimately empower tumor progression by manipulating the genetic program of evolving tumor cells (Bernards and Weinberg, 2002) .
While we present evidence for a large-scale transcriptional downregulation of Ras-responsive genes, target gene inactivation may occur also at the post-transcriptional level. Ras signaling affects protein stability (Sears et al., 2000) , post-translational modification (Bonni et al., 1999; Rivedal and Opsahl, 2001 ) and protein degradation (Saha et al., 2001) . Of note, identical cellular targets can be affected by Ras-mediated transcriptional and post-transcriptional deregulation. For instance, intercellular gap-junctional communication in ovarian epithelial cells may be perturbed by downregulation of connexin 43 transcription (this paper) and by MEK-dependent phosphorylation of the protein (Rivedal and Opsahl, 2001 ). Oncogenic Ras may subvert TGF-b signaling in two different ways: by downregulating TGF-b receptor expression (this paper) and by degrading the tumor suppressor Smad4, a downstream effector protein (Saha et al., 2001) .
Regarding the relevance of the ROSE cell culture model described here for ovarian carcinoma, it is important to note that KRAS mutations are rare in serous tumors. Mutational activation of KRAS is prevalent only in ovarian tumors of the mucinous type, including cystadenomas, tumors of borderline malignancy and carcinomas (Enomoto et al., 1991; Mok et al., 1993; Ichikawa et al., 1994; Cuatrecasas et al., 1997) . However, the RAS signaling pathway may be alternatively activated by mechanisms not involving 
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Oxygen regulated protein ORP150 C C Transcriptome profiling in KRAS transformation OI Tchernitsa et al genetic damage to KRAS, for example, by enhanced postreceptor signaling as observed in ovarian cancer cell lines (Patton et al., 1998) , by alterations in factors capable of regulating RAS function (van Engeland et al., 2002) or by activating mutations in the downstream effector B-Raf as shown in many tumors including ovarian carcinomas (Davies et al., 2002) . We have compared the results of KRAS-related transcriptional profiling in ROSE cells with those obtained in one selected microarray-based analysis of differential gene expression in ovarian epithelial malignancies (Welsh et al., 2001) . Of 29 genes underexpressed in serous papillary ovarian carcinomas, 14 (48%) were transcribed in normal ROSE cells and downregulated in KRAS-transformed ROSE A2/5 cells. Of 40 genes overexpressed in ovarian carcinomas relative normal ovaries, 26 (65%) were upregulated in transformed ROSE cells. Although Welsh et al. used RNA prepared from whole ovaries rather than from ovarian epithelium for contrasting carcinoma-specific expression and their results may not be representative for all types of ovarian cancers, it is tempting to speculate that many of the markers identified are responsive to RAS-mediated signal transduction in tumors as well. The decisive role of RAS signaling in epithelial transformation is underscored by gene transfer experiments aimed at reconstructing cancer by sequential introduction into normal epithelial cells of telomerase, the SV40 large tumor antigen, achieving inactivation of TP53 and RB tumor suppressors, and of mutated HRAS (Hahn et al., 1999) .
Ras-responsive genes are organized in signal-regulated transcriptional modules
We defined subsets of Ras-responsive genes by virtue of their differential sensitivity toward inhibition of effector kinases (Figures 4 and 5, Table 2 ) suggesting an organization of the targets in signal-regulated transcriptional modules (SITMs) (Figure 7 ). When we blocked the Raf/MEK/ERK pathway in KRAS-transformed ROSE cells with the MEK inhibitor PD 98059, 58 targets exhibited mRNA levels indistinguishable from those in normal ROSE 199 cells, while 40 genes partially reached pretransformation mRNA levels. Most importantly, the reversion of transcriptional alterations was coupled with the reversal of EMT and loss of anchorage-independent proliferation (Figure 1) , assigning a direct role in the control of neoplastic phenotypes to both Erk modules of upregulated and downregulated target genes, respectively. The PI3K-sensitive module comprises 27 upregulated targets, as indicated by their transcriptional response toward inhibition by LY 249002 (Figure 4 , Table 1 ). We did not find any evidence for a PI3K-dependent module of repressed genes. This may be due to the insensitivity of responsive regulators toward the experimental conditions used in ROSE A2/5 cells. Alternatively, the lack of effects on repressed targets caused by PI3K inhibition may be explained by crosstalk between effector kinase signaling (Zimmermann and Moelling, 1999) . In total, 19 genes grouped in the PI3K module are coregulated by MEK signaling ( Table 2 ). The PI3K inhibitor did not significantly affect the transformed characteristics of A2/5 cells ( Figure 5 ), suggesting that the transcriptional changes associated with the signaling blockade are irrelevant for the analysed phenotypes. Thus, the number of critical targets in Erk modules 1 and 2 can be narrowed down further: We conclude that execution of EMT, anchorage independence and possibly related phenotypes is mainly achieved by MEK signaling in conjunction with the deregulation of 79 genes in two ERK-modules (i.e. 98 genes minus 19 genes, coregulated by PI3K signaling and not correlated with transformation-related phenotypic changes). The non-MEK/non-PI3K modules, which are unaffected by inhibition of MEK-and PI3K-signaling, harbor additional targets known to be involved in various aspects of growth control and tumor progression, for example, the metastasis-enhancing GTPase RhoC, the negative growth regulators and tumor suppressor genes TSC36, Gas1, E-cadherin, WT1, TGF-b II receptor, Cx43 and four tropomyosin isoforms (see Table 3 for a description of functions). There are obvious candidate signaling pathways downstream of RAS that play an important role in the control of neoplastic phenotypes (Campbell et al., 1998) , however their roles have not yet been defined in the ROSE model.
Differentially expressed transcriptional regulators contribute to KRAS-mediated transformation
While the transcriptional regulators Elk1, SRF, ATF2 and others are well known to integrate postreceptor (Campbell et al., 1998; Downward, 1998a; Malumbres and Pellicer, 1998) their specific contribution to neoplasia is not clear. The transcription factors Fra-1, WT1 and others, differentially expressed in A2/5 relative to ROSE 199 cells (Table 1) , provide novel clues to understanding the mechanisms of transformation-related deregulation of target gene acticity. Fra-1 upregulation was previously described in tumors (Risse et al., 1998; Zajchowski et al., 2001) . Tables 1 and 2 were not analysed for sensitivity towards kinase inhibitors. X-Z, signal transduction molecules not analysed in ROSE cells resulting in an attenuation of Fos-regulated gene expression (Kessler et al., 1999) . Thus, it is possible that loss of AP-1 activity is partially responsible for the excessive downregulation of target genes. Silencing Fra-1 expression by RNA interference reduced proliferation of KRAS-transformed ROSE cells significantly, however, to a lesser extent than knocking-down KRAS-expression ( Figure 6 ). We conclude that the upregulation of the Ras-responsive gene Fra-1 is necessary but not sufficient for the proliferative capacity of A2/5 cells. It will be interesting to find out, if parallel silencing of coregulated Ras-responsive genes can complement Fra-1 knockdown to achieve full reversion of transformed phenotypes and growth inhibition. The Wilm's tumor suppressor gene (WT1) gene encoding a Cys-His zinc-finger transcription factor, which functions as a transcriptional repressor and activator, is negatively regulated by RAS signaling via the non-ERK/non-PI3K-module (Table 2, Figure 7 ). The WT1 gene is a known suppressor of Ras-mediated transformation (Luo et al., 1995) . E-cadherin is thought to mediate the tumor-suppressing activity of the WT1 protein which binds to and stimulates the E-cadherin promoter (Hosono et al., 2000) . Although there is also some evidence for a Ras-suppressible E-box in the Ecadherin promoter (Grooteclaes and Frisch, 2000) , the downregulation of WT1 may account for the loss of Ecadherin expression in transformed ROSE cells. Since impairment of WT1 function has been observed in ovarian carcinoma (Schorge et al., 2000) , other targets critical for ovarian tumor pathogenesis may be controlled by the same mechanism.
Besides the potential role of transcriptional regulators such as Fra-1 and WT-1 in tumor suppressor gene downregulation in KRAS-transformed ROSE cells, methylation may be involved as a major epigenetic mechanism (Rountree et al., 2001) . Ras signaling can indeed mediate enhanced DNA methylation activity (Macleod et al., 1995) . Preliminary studies suggest that treatment of Ras-transformed cells with the demethylating agent 5-aza-2-deoxycytidine can partially restore pretransformation mRNA levels of some target genes (CS and PL, unpublished) .
In summary, the ROSE cell culture model provides an ideal tool for assessing the functional contributions to ovarian epithelial transformation of genes identified by expression profiling and for preclinical validation of novel therapeutic targets.
Materials and methods
Cell culture and DNA transfections ROSE 199 cells (Adams and Auersperg, 1985) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum and antibiotics. Transformed ROSE A2/5 cells were obtained after cotransfection with the KRAS (C12V) gene, amplified by PCR from cDNA of SW480 human colon carcinoma cells using gene-specific primers and cloned under the control of the elongation factor promoter into the expression vector pEF-BOS (Mizushima and Nagata, 1990) , and the pSV2neo gene followed by selection in DMEM supplemented with G418 (400 mg/ml). We used A2/5 cells from stocks cryopreserved early after isolation and maintained in culture not longer than 30 days prior to RNA isolation and construction of subtracted cDNA libraries.
Inhibitor studies and proliferation assay
The MEK inhibitor PD 98059 (Dudley et al., 1995) (Alexis; Gru¨nberg, Germany) was dissolved in DMSO to a final concentration of 50 mM. A2/5 cells were treated for 2 days with PD 98059 at a final concentration of 50 mM. Anchorageindependent proliferation was measured semiquantitatively in cultures grown on microtiter dishes coated with poly-2-hydroxyethyl methacrylate (poly-HEME; Sigma). A volume of 75 ml of a 5 mg/ml poly-HEME stock solution, dissolved in 95% ethanol, were added to the wells and allowed to dry for 72 h at 371C. Cell suspensions (1000 cells/well) were seeded on coated dishes. Growth was monitored after 5 days using an XTT-based colorimetric assay (Roche, Mannheim, Germany) based on formazan dye formation in metabolically active cells measured at 490 nm. The PI3K inhibitor LY 294002 (Vlahos et al., 1994) (Alexis) was dissolved in ethanol to a final concentration of 10 mM. A2/5 cells were treated for 2 days with LY 294002 at a final concentration of 10 mM.
RNA interference
Short RNA oligonucleotides targeting Fra-1 were chemically synthesized (Dharmacon, Lafayette, CO, USA). The following RNA oligonucleotides were used: CUACCCGUUGUCAU-CUCCUUUCTT (Fra-1, sense) and TTGAUGGGCAACA-GUAGAGGAAAG (Fra-1, antisense); RNA oligonucleotides targeting HRAS and KRAS were synthesized by in vitro transcription using the Silencer siRNA Construction Kit (Ambion). The following DNA oligonucleotides were used as templates: AATTCCTGTAGGAATCCTCTA (KRAS, sense), AAGGACATCCTTAGGAGATAA (KRAS, antisense), AATCTTGCCCACACCTACGGC (HRAS, sense), AGAACGGGTGTGGCTGCCGAA (HRAS, antisense). For annealing of siRNAs, 400 mM single strands were incubated in annealing buffer as described (Elbashir et al., 2001) .
At 24 h prior to transfection, 4 Â 10 4 A2/5 cells were seeded into six-well plates. Transfection of siRNA was carried out using Oligofectamine (Life Technologies) and 0.2 mM siRNA duplex derived from chemically synthesized RNA oligonucleotides per well as described previously (Elbashir et al., 2001) . siRNA duplexes obtained after enzymatic synthesis were applied at a final concentration of 1 nM. Cells were treated with siRNA twice in 24 h-intervals and analysed 28-48 h after the first treatment. The effects of siRNA on the proliferation of cells was determined by XTT assays in triplicate transfections.
Identification of differentially expressed sequences by SSH
Total RNA was prepared from subconfluent cultures as described (Chomczynski and Sacchi, 1987) . Messenger RNA was isolated from 1 mg of total RNA using the mRNA Separator kit (Clontech, Palo Alto, CA, USA). We performed cDNA synthesis and subtraction with the PCR-Selectt cDNA subtraction kit (Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol with modifications: We used a driver/tester volume ratio of 2 : 1 in the first hybridization. In all, 26 cycles of the primary PCR and 10 cycles of secondary PCR were performed with the Advantage cDNA polymerase mix (Clontech, Palo Alto, CA, USA). To evaluate the efficiency of cDNA subtraction, we compared the transcript levels of the housekeeping gene GAPDH by RT-PCR in subtracted and unsubtracted cDNA populations from ROSE 199 and A2/5 RNA, respectively. Detection of GAPDH sequences for both subtractions required 28 PCR cycles with subtracted cDNA as template, while only 18 cycles were sufficient to amplify GAPDH from control cDNAs. Furthermore, transcript levels of genes known to be differentially expressed in the cell pair under investigation were tested by RT-PCR. As expected, KRAS-specific sequences were enriched in subtracted versus unsubtracted A2/5 cDNA. Lysyl oxidase levels were increased in subtracted versus unsubtracted ROSE 199 cDNA and decreased from a low level in unsubtracted A2/5 cDNA to a nondetectable level in subtracted A2/5 cDNA.
Subtracted cDNA sequences were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and 10 ng were inserted into the T/A cloning vector pCR2.1 (Invitrogen, Leek, The Netherlands). Individual transformants carrying cDNA fragments were isolated from white colonies on X-gal/IPTG agar plates. To assess the quality of the library with respect to redundancy and specificity, we randomly picked 35 cDNA clones from each library DNA and determined their sequence. We also analysed differential expression of the individual cDNA sequences on Northern blots with 10 mg of total RNA from ROSE 199 cells.
Sequencing reactions were performed with the M13 universal primer using the BigDye sequencing kit (Perkin Elmer) according to the manufacturer's protocol. Sequences were determined on an ABI377 sequencer. We discontinued sequencing of the cDNA inserts of subtracted libraries when the number of redundant sequences significantly exceeded that of novel clones. Clustering was performed using the gap4 software (Staden package). Sequence homology searches were done against GenBank (nr) and Expressed Sequence Tag (dbest) databases using the BLASTN program at NCBI (http:// www.ncbi.nlm.nih.gov/BLAST). Sequence management was performed with database tools developed in our laboratory.
Reverse and standard Northern blot analysis
Nonredundant plasmid DNA probes of all identified fragments were transferred to 96-well microtiter plates. Using PCR-Selectt adaptor-specific primers, we carried out PCR amplification for 30 cycles (30 s 941C, 30 s 681C, 90 s 721C). The average size of the inserted fragments was 800 bp. The PCR amplified inserts were blotted onto duplicate 25 Â 12 cm Nytran nylon membranes (Schleicher and Schuell, Dassel, Germany). Reverse Northern analysis was performed as described (von Stein et al., 1997) except for different hybridization conditions. For prehybridization of membranes, we used 5 Â Denhardt's reagent, 5 Â SSC, 50 mM phosphate buffer, 0.5% SDS, 100 ng/ml tRNA at 651C for 3 h. Hybridization was performed in the same buffer without Denhardt's reagent and 50 mM phosphate buffer at 651C for 16 h.
For conventional Northern blot analysis, 10 mg of total RNA were fractionated by electrophoresis through 1% agarose gels containing formaldehyde and blotted in 20 Â SSC onto Protran nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany) . To facilitate analysis of multiple samples, the size of individual hybridization membranes containing two RNA samples was reduced to 1 Â 3 cm. The cDNA fragments were labeled with [ 32 P]dCTP using the ReadyPrime system (Amersham, Braunschweig). Hybridization was performed in ExpressHyb hybridization buffer (Clontech, Palo Alto, CA, USA) at 681C overnight. Membranes were washed 2-times in 2 Â SSC, 0.1% SDS at 421C for 20 min, 2-times in 0.1 Â SSC, 0.1% SDS at 661C for 30 min an exposed to X-ray films at À801C for 6 h -3 days.
Western blot analysis
Cell extracts were prepared and processed for Western blot analysis as described recently (Zuber et al., 2000) except for the determination of phospho-AKT levels. Cellular extracts for phospho-AKT detection were prepared by lysis in a buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue. The following antibodies were used: phospho-AKT (Ser473), p44/42 MAP kinase, phospho-p44/42 MAP kinase (Thr202/ Tyr204), histone H3 antibodies (Cell Signaling, Technology, Beverly, MA, USA), Fra-1 antibody CR20 (Santa Cruz 
